Cannabis Health Research: New Findings for June 2026

🔬 Recent cannabis research continues to highlight significant gaps in our understanding of drug interactions and cannabinoid bioavailability, both of which have direct implications for patient safety in clinical settings. The variability in how different cannabis products are absorbed and metabolized underscores the challenge clinicians face when counseling patients about dosing consistency and potential medication interactions, particularly for patients on narrow-therapeutic-index drugs or complex polypharmacy regimens. A key caveat is that much of the emerging research stems from heterogeneous study designs and populations, making it difficult to establish generalizable clinical recommendations across diverse patient groups. Until we have more standardized data on cannabinoid pharmacokinetics and drug-drug interactions, the most practical approach for clinicians is to maintain a detailed medication history that includes all cannabis use, counsel patients on the unpredictability of different formulations, and consider consulting toxicology or pharmacology resources when prescribing to established cannabis